GYRE
Gyre Therapeutics, Inc.
GYRE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
GYRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
GYRE's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
GYRE PE Valuation
GYRE has no meaningful PE right now: it lost money over the past year.
GYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect GYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
GYRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.05 | +$2.86 |
| Q3 2024 | -$1.26 | +$19.44 |
| Q2 2024 | -$1.87 | +$20.63 |
| Q1 2024 | -$2.93 | -193% |
| Q4 2023 | -$2.81 | +$1.09 |
| Q3 2023 | -$20.70 | -463% |
| Q2 2023 | -$22.50 | -$18.60 |
| Q1 2023 | $3.15 | +$41.25 |
GYRE lost $0.27 per share over the past year, a smaller loss than the year before.
GYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.9M | +7.8% |
| Q2 2026 | $29.1M | +8.7% |
| Q1 2026 | $22.5M | +2.1% |
| Q4 2025 | $37.2M | +33% |
| Q3 2025 | $30.6M | +20% |
| Q2 2025 | $26.8M | +6.1% |
| Q1 2025 | $22.1M | -19% |
| Q1 2022 | $794K | -46% |
GYRE's revenue has grown year over year for six quarters in a row: $33M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | -27 points |
| Q2 2026 | -49% | -58 points |
| Q1 2026 | -42% | -52 points |
| Q4 2025 | 0.3% | -1.8 points |
| Q3 2025 | 23% | +6.1 points |
| Q2 2025 | 8.1% | -4.8 points |
| Q1 2025 | 10% | -19 points |
| Q4 2024 | 2.1% | N/A |
GYRE's operating margin was −4.6% last quarter, down 27 points from the same quarter a year ago.
GYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | -224% |
| Q2 2026 | -$17M | -1027% |
| Q1 2026 | $3M | +$3.3M |
| Q4 2025 | -$5.8M | -$3.1M |
| Q3 2025 | $4M | +288% |
| Q2 2025 | $1.8M | +$8.8M |
| Q1 2025 | -$251K | -109% |
| Q3 2024 | $1M | +$4.3M |
GYRE has burned cash in most quarters: −$25M over the past year, against $3M the year before.
GYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +5.7M shares |
| 1 year | +2.2% | +2.3M shares |
| 3 years | +4955% | +104M shares |
| 5 years | +7124% | +105M shares |
GYRE has 106M diluted shares, up 2.2% from a year ago.
GYRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q1 2023 | -1.3x | Net Cash |
| Q3 2022 | -2.0x | Net Cash |
GYRE has more cash than debt.
GYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 10.3 | Oversold |
GYRE's weekly RSI is 32 (neutral) and its Stochastic is 10 (oversold).
GYRE PE vs Healthcare Sector
| Metric | GYRE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GYRE has no meaningful PE right now: it lost money over the past year.
GYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.88 | 27% below |
| 20 week MA | $6.33 | 32% below |
| 50 week MA | $6.89 | 38% below |
| 100 week MA | $7.91 | 46% below |
| 200 week MA | $9.42 | 54% below |
GYRE is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
GYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.4 | $97.1 | -4.3% |
| 2021 | $97.1 | $15.9 | -84% |
| 2022 | $15.9 | $7.50 | -53% |
| 2023 | $7.50 | $25.7 | +243% |
| 2024 | $25.7 | $12.5 | -52% |
| 2025 | $12.5 | $7.26 | -42% |
| 2026 YTD | $7.26 | $4.30 | -41% |
GYRE's yearly returns have swung widely, from +243% in 2023 to −84% in 2021. It's down 41% so far in 2026.